Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of “Hold” from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been given an average recommendation of “Hold” by the six analysts that are covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $52.33.

A number of equities research analysts recently commented on the company. Benchmark reiterated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Wells Fargo & Company dropped their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. JPMorgan Chase & Co. upped their target price on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Bank of America dropped their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. Finally, StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in OMCL. Apollon Wealth Management LLC acquired a new position in Omnicell in the 3rd quarter valued at $249,000. Sumitomo Mitsui Trust Group Inc. acquired a new position in Omnicell in the 3rd quarter valued at $32,721,000. Victory Capital Management Inc. raised its stake in Omnicell by 11,982.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock valued at $50,071,000 after purchasing an additional 1,138,921 shares during the last quarter. Curi RMB Capital LLC raised its stake in Omnicell by 0.7% in the 3rd quarter. Curi RMB Capital LLC now owns 88,815 shares of the company’s stock valued at $3,872,000 after purchasing an additional 651 shares during the last quarter. Finally, Royce & Associates LP acquired a new position in Omnicell in the 3rd quarter valued at $811,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Performance

Shares of Omnicell stock opened at $32.93 on Friday. The company has a market capitalization of $1.54 billion, a PE ratio of 121.97, a P/E/G ratio of 7.53 and a beta of 0.85. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company has a 50-day simple moving average of $40.27 and a two-hundred day simple moving average of $43.10. Omnicell has a one year low of $25.12 and a one year high of $55.75.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Research analysts expect that Omnicell will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.